Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

BACKGROUND: A nadir Prostate-Specific Antigen (nPSA) of 0.06 ng/mL has been shown to be a strong independent predictor of biochemical recurrence-free survival (bRFS) in patients with intermediate or high-risk (HR) prostate cancer treated with definitive external beam radiation therapy (RT) and andro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Zeina, Khader, Jamal, Bulbul, Muhammad, Khauli, Raja B., Andraos, Therese Y., Shamseddine, Ali, Mukherji, Deborah, Geara, Fady B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743609/
https://www.ncbi.nlm.nih.gov/pubmed/36503556
http://dx.doi.org/10.1186/s12894-022-01145-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743609/
https://www.ncbi.nlm.nih.gov/pubmed/36503556
http://dx.doi.org/10.1186/s12894-022-01145-x

Ejemplares similares